
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up to $2.2 billion for Septerna. This includes more than $200 million in upfront and short-term milestone payments, plus future rewards tied to research, development… read on > read on >